<DOC>
	<DOCNO>NCT02224703</DOCNO>
	<brief_summary>To investigate potential antiepileptic effect cannabidiol ( GWP42003-P ) child young adult Dravet syndrome .</brief_summary>
	<brief_title>GWPCARE2 A Study Investigate Efficacy Safety Cannabidiol ( GWP42003-P ) Children Young Adults With Dravet Syndrome</brief_title>
	<detailed_description>This study 1:1:1 randomize , double-blind , 14-week comparison two Dose Levels GWP42003-P versus placebo . A 28-day screening period prior randomization ( establish baseline parameter ) precede treatment period , consist two-week titration period follow 12-week maintenance period . The study aim determine efficacy , safety tolerability GWP42003-P compare placebo . The High Dose Level recommend Data Safety Monitoring Committee ( DSMC ) assessment safety pharmacokinetic data Part A study GWEP1332 . The Low Dose Level define 50 % High Dose Level . The first subject enroll study DSMC review safety data Part A study GWEP1332 . Following study completion , subject invite continue receive GWP42003-P open label extension ( OLE ) study ( separate protocol ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Epilepsies , Myoclonic</mesh_term>
	<criteria>Key Subject must male female age 2 18 year ( inclusive ) . Subject must document history Dravet syndrome completely control current antiepileptic drug . Subject must take one antiepileptic drug dose stable least four week . All medication intervention epilepsy ( include ketogenic diet vagus nerve stimulation ) must stable four week prior screen subject willing maintain stable regimen throughout study . Key Subject clinically significant unstable medical condition epilepsy . Subject clinically relevant symptom clinically significant illness four week prior screen randomization , epilepsy . Subject currently use past use recreational medicinal cannabis , synthetic cannabinoid base medication ( include SativexÂ® ) within three month prior study entry unwilling abstain duration study . Subject know suspected hypersensitivity cannabinoids excipients investigational medicinal product . There plan subject travel outside country residence study . Any history suicidal behavior suicidal ideation type four five ColumbiaSuicide Severity Rating Scale ( Children 's ) screening .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Cannabidiol</keyword>
	<keyword>CBD</keyword>
	<keyword>GWP42003-P</keyword>
</DOC>